Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Denali Therapeutics Inc. DNLI
$27.73
+$0.04 (0.14%)
На 18:00, 12 мая 2023
+228.16%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3793056640.00000000
-
week52high
39.43
-
week52low
20.24
-
Revenue
108463000
-
P/E TTM
-11
-
Beta
1.32491300
-
EPS
-2.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 10:59
Описание компании
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Berenberg | Buy | 23 июн 2022 г. | |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 06 янв 2022 г. |
| Oppenheimer | Outperform | 21 сент 2021 г. | |
| Morgan Stanley | Overweight | Overweight | 16 авг 2021 г. |
| B of A Securities | Buy | 02 ноя 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 08 ноя 2022 г. |
| Cowen & Co. | Outperform | 05 дек 2022 г. | |
| SVB Leerink | Outperform | 30 янв 2023 г. | |
| Morgan Stanley | Overweight | Overweight | 25 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Schuth Alexander O. | D | 98937 | 10000 | 17 янв 2023 г. |
| Schuth Alexander O. | D | 497173 | 114 | 17 янв 2023 г. |
| Schuth Alexander O. | D | 497287 | 9886 | 17 янв 2023 г. |
| Schuth Alexander O. | A | 507173 | 10000 | 17 янв 2023 г. |
| Ho Carole | D | 177454 | 1459 | 09 янв 2023 г. |
| Ho Carole | D | 178913 | 1451 | 06 янв 2023 г. |
| Watts Ryan J. | D | 2223664 | 4800 | 05 янв 2023 г. |
| Schuth Alexander O. | D | 497173 | 2636 | 05 янв 2023 г. |
| Krognes Steve E. | D | 146498 | 2970 | 05 янв 2023 г. |
| Ho Carole | D | 180364 | 2636 | 05 янв 2023 г. |
Новостная лента
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
Zacks Investment Research
09 мая 2023 г. в 14:31
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:02
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.53 per share a year ago.
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?
Zacks Investment Research
29 мар 2023 г. в 13:00
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
Zacks Investment Research
28 февр 2023 г. в 10:33
Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
27 февр 2023 г. в 18:49
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?